The classic website will no longer be available as of June 25, 2024. Please use the modernized ClinicalTrials.gov.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 2 for:    BNT122-01
Previous Study | Return to List | Next Study

Epidemiological Study to Monitor Study Participants With Resected Stage II (High Risk) or Stage III Colorectal Cancer for Circulating Tumor DNA Before, During and After Their Treatment With Adjuvant Chemotherapy

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04813627
Recruitment Status : Recruiting
First Posted : March 24, 2021
Last Update Posted : April 11, 2024
Sponsor:
Information provided by (Responsible Party):
BioNTech SE

Study Description
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information
Brief Summary:

This is a multi-site epidemiological study designed to monitor circulating tumor DNA (ctDNA) status in participants with Stage II (high risk)/III colorectal cancer (CRC) following resection/prior to adjuvant chemotherapy (AdCTx), during the course of AdCTx and for a period of 630 days thereafter, according to CRC stages and disease characteristics.

Participants receive no therapeutic intervention as part of this study. This study will identify participants who might be potential candidates for the clinical trial BNT122-01 (NCT04486378), a study of RO7198457 after completion of standard AdCTx in this patient population. Based on the eligibility criteria for that trial, this study will identify participants with confirmed Stage II (high risk)/III CRC that are positive for ctDNA after resection and are therefore at high risk of disease recurrence to enrich the BNT122-01 study cohort. These participants will have the option to enter screening for BNT122-01 at Screening Visit 2 of that trial if they meet the eligibility criteria of BNT000-001 during screening. Data from the assessments from BNT000-001 will be carried across to the BNT122-01 trial where feasible.


Condition or disease Intervention/treatment
Colorectal Cancer Stage II Colorectal Cancer Stage III Procedure: Regular blood sample collection for ctDNA assessment

Study Design
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Layout table for study information
Study Type : Observational
Estimated Enrollment : 1500 participants
Observational Model: Cohort
Time Perspective: Prospective
Official Title: Epidemiological Study to Determine the Prevalence of ctDNA Positivity in Participants With Stage II (High Risk) or Stage III CRC After Surgery With Curative (R0) Intent and Subsequent Adjuvant Chemotherapy With Monitoring of ctDNA During Clinical Follow-up
Actual Study Start Date : July 2, 2021
Estimated Primary Completion Date : July 2024
Estimated Study Completion Date : July 2024
Groups and Cohorts
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Group/Cohort Intervention/treatment
Participants with R0 resected Stage II (high risk) or Stage III CRC
The participants eligible for this epidemiological study are those with completely resected Stage II (high risk)/III CRC (per the American Joint Committee on Cancer (AJCC) 8th revised edition staging system) due to receive standard of care chemotherapy for at least 3 months following surgery.
 Procedure: Regular blood sample collection for ctDNA assessment
Blood samples for in vitro testing of ctDNA status will be drawn at study visits every three months


Outcome Measures
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :
  1. Occurrence of ctDNA positivity in the post-surgery/pre-AdCTx blood sample [ Time Frame: 4 to 8 weeks after surgery and within 7 days prior up to the day of start of AdCTx ]
    Blood sample taken post-surgery and pre-adjuvant chemotherapy.

  2. Occurrence of ctDNA positivity in the first post-AdCTx blood sample [ Time Frame: 14 to 21 days after last AdCTx treatment ]
    Blood sample taken post-adjuvant chemotherapy.


Secondary Outcome Measures :
  1. Transfer of participants from the BNT000-001 study to the BNT122-01 clinical trial [ Time Frame: 4 weeks following Visit 1 (upon availability of ctDNA positivity status) ]
    The absolute and relative frequency of participants that will transfer to the BNT122-01 clinical trial from this epidemiological study will be reported.


Biospecimen Retention:   Samples With DNA
  • Blood and tumor tissue samples collected for ctDNA assessment will be destroyed when subsequent clinical validity and/or bridging studies to support the validation of ctDNA assay are completed (where the samples are not exhausted).
  • Remaining biospecimens from a particular participant must be destroyed if the participant specifically requests that their archival specimens are destroyed upon their withdrawal from the study.
  • Remaining archival tissue blocks will be returned to the site upon request or no later than the time of final closure of the study database, whichever occurs first. For participants who are not eligible for enrollment in study BNT122-01, remaining archival tissue blocks will be returned to the site no later than 6 months after eligibility determination.

Eligibility Criteria
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population
Participants with Stage II (high risk)/III CRC after resection (R0) and that are scheduled to receive AdCTx will be enrolled in this study.
Criteria

Inclusion Criteria:

  • Must have given informed consent indicating that they understand the purpose of and procedures required for the study and are willing to participate in the study.
  • Age ≥ 18 years old at time of signing the informed consent form.
  • Ability to comply with the study protocol, in the investigator's judgment.

  • Must have Stage II/Stage III rectal cancer or Stage II (high risk)/Stage III colon cancer per AJCC 2017 that has been surgically totally resected (R0 confirmed by pathology report). Stage II (high risk) colon cancer is defined as (any of):

    • T4
    • Grade ≥ 3
    • Clinical presentation with bowel obstruction or perforation
    • Histological signs of vascular, lymphatic or perineural invasion
    • < 12 nodes examined
  • Adequate tumor material in formalin-fixed paraffin embedded (FFPE) blocks or as sectioned tissue (only upon approval by sponsor) must be available, preferably from resection. The specimen should be submitted along with an associated pathology report. Multiple samples may be provided as available, but priority should be given to tissue with the highest tumor content and lowest necrotic area.
  • Intention to receive a standard of care adjuvant chemotherapy (AdCTx) within 8 weeks post-surgery, and be scheduled for at least 3 months of treatment (including rest days) according to the treating physician or investigator.
  • Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1.
  • Adequate end-organ function.

Exclusion Criteria:

  • Induction of neoadjuvant systemic therapy prior to resection of CRC.
  • Prior systemic investigational therapy.

  • Positive serology for hepatitis B (unless immune due to vaccination or resolved natural infection or unless passive immunization due to immunoglobulin therapy):

    • Positive test for antibodies to hepatitis B core antigens (anti HBc) and
    • Negative test for antibodies to hepatitis B surface antigens (anti HBs).
  • Active hepatitis C virus (HCV) infection; participants who have completed curative antiviral treatment with HCV viral load below the limit of quantification by polymerase chain reaction (PCR) are allowed.
  • Participant has a history of human immunodeficiency virus (HIV) antibody positivity, or tests positive for HIV at screening.
  • Residual tumor classification following surgery other than R0 (microscopic margin-negative resection).

  • Participants with known past or current malignancy other than inclusion diagnosis, except for:

    • Cervical carcinoma of Stage 1B or less.
    • Non-invasive basal cell or squamous cell skin carcinoma.
    • Non-invasive, superficial bladder cancer.
    • Prostate cancer with a current PSA level < 0.1 ng/mL.
    • Any curable cancer with a complete response (CR) of > 2 years duration.
  • Participant has not started standard of care AdCTx within 8 weeks post-surgery.
  • Participant has received less than 3 months (including rest days) of AdCTx treatment.
  • Inadequate tumor material (either quality or quantity) to support circulating tumor DNA (ctDNA) analysis.
  • Participants who have had prior splenectomy.
Contacts and Locations
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04813627


Contacts
Layout table for location contacts
Contact: BioNTech clinical trials patient information +49 6131 9084 ext 0 patients@biontech.de

Locations
Show Show 73 study locations
Sponsors and Collaborators
BioNTech SE
Investigators
Layout table for investigator information
Study Director: BioNTech Responsible Person BioNTech SE
More Information
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information
Layout table for additonal information
Responsible Party: BioNTech SE
ClinicalTrials.gov Identifier: NCT04813627    
Other Study ID Numbers: BNT000-001
First Posted: March 24, 2021    Key Record Dates
Last Update Posted: April 11, 2024
Last Verified: April 2024
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Colorectal Neoplasms
Intestinal Neoplasms
Gastrointestinal Neoplasms
Digestive System Neoplasms
Neoplasms by Site
Neoplasms
 Digestive System Diseases
Gastrointestinal Diseases
Colonic Diseases
Intestinal Diseases
Rectal Diseases